Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.

ABSTRACT:

Background

Obesity and metabolic disease are increasingly prevalent in patients with inflammatory bowel disease (IBD) and can influence disease activity and treatment outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss and metabolic control, yet their safety and effects in IBD remain uncertain as patients with IBD have been excluded from pivotal trials.

Aims

To systematically evaluate the weight-related, metabolic, IBD-specific, and safety outcomes of GLP-1 receptor agonists in adults with IBD.

Methods

We conducted a systematic review according to PRISMA guidelines (PROSPERO CRD42025628850). We searched MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov to 9 September 2025 for studies evaluating GLP-1 RAs in adults with

SUBMITTER: Maracle B 

PROVIDER: S-EPMC12690230 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature